<DOC>
	<DOCNO>NCT00255593</DOCNO>
	<brief_summary>Current strategy medical management transplant patient largely focused prevention treatment T-lymphocyte mediate process . However increase evidence suggest B-lymphocytes role otherwise classic T-cell mediate rejection transplant ability act antigen present cell T-cell activator . Thus significant medical need effective therapy target B cell transplant patients.One potential therapy would use rituximab , monoclonal antibody B-cells renal transplant patient . In present study efficacy safety prophylactic rituximab study .</brief_summary>
	<brief_title>Safety Efficacy Study Rituximab Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients age 18 year Recipients first second renal transplant Recipients kidney live cadaveric donor Single organ recipient ( kidney ) Patients provide write informed consent Patients cooperative able complete assessment procedure Patients receive immunosuppressive therapy within precede 28 day Recipients HLAidentical sibling kidney Patients flowPRA &gt; 50 % within 6 month prior enrolment Recent history malignancy Active infection Pregnant lactating female Women childbearing potential willing use reliable form contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Rituximab</keyword>
</DOC>